SANTA CLARA, Calif. & SAN DIEGO–(BUSINESS WIRE)–Affymetrix Inc. (NASDAQ:AFFX) and Reveal Biosciences LLC, an advanced tissue technologies company, today announced a partnership agreement through which Reveal will use Affymetrix ViewRNA® ISH products for tissue samples to provide RNA in situ hybridization (ISH) staining, imaging, and quantification services using the company’s proprietary image analysis software, ImageDx™.
“RNA in situ hybridization is fast becoming the method of choice for researchers wanting to validate established and novel biomarkers for translational and clinical research,” said Guy Afseth, marketing director for Affymetrix’ oncology portfolio. With Affymetrix’ ViewRNA ISH portfolio for tissue samples, researchers can rapidly design assays for virtually any mRNA transcript or long noncoding RNA in any tissue type. ViewRNA assays utilize branched DNA signal amplification technology to achieve unparalleled sensitivity and specificity, enabling the visualization of targets at the single-molecule level within the context of the tissue morphology.
“We are thrilled to partner with Affymetrix to provide high-quality services using ViewRNA products. Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software, ImageDx™, form a powerful platform for the localization and quantification of mRNA in tissue samples,” said Dr. Claire Weston, CEO and founder of Reveal Biosciences. “This highly sensitive technology is changing the face of mRNA biomarker screening and analysis for translational research and diagnostics.”
About Reveal Biosciences
Reveal Biosciences is a leading provider of advanced tissue technology services and tissue-based research. The company’s portfolio includes in situ hybridization (ISH), immunohistochemistry (IHC), immunofluorescence (IF), and histology. Reveal enhances these services with proprietary technologies for NGPx™ Next Generation Pathology, multiplexing, whole-slide imaging, and ImageDx™image analysis software as a service. For more information about Reveal Biosciences, please visit: https://www.revealbio.com.
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness. Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit www.affymetrix.com.
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, and ViewRNA trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.
Affymetrix Media Contact Mindy Lee-Olsen, 408-731-5523 Vice President, Marketing Services [email protected] Investor Contact Doug Farrell, 408-731-5285 Vice President, Investor Relations [email protected]
Reveal Biosciences Media and Investor Contact Ami Lau, 858-274-3663 External Relations [email protected]